Talcum Powder Lawsuit Timeline: The MDL, Bankruptcy Detours, and the 2026 Evidence Review

2016 to 2020: centralization and the first expert-evidence ruling

The federal story starts on October 5, 2016, when the Judicial Panel on Multidistrict Litigation created MDL 2738 in the District of New Jersey. The transfer order covered actions alleging that prolonged perineal use of Johnson & Johnson talcum powder products can cause ovarian or uterine cancer. Centralization was a case-management decision: it placed recurring discovery and pretrial questions before one federal judge. It did not certify a class, decide that talc caused cancer, or remove independently filed cases from state courts.

After years of discovery, the court issued a major Rule 702 opinion in April 2020. Rule 702 governs whether expert testimony is sufficiently qualified, reliable, and fitted to the dispute to be heard. The court limited some opinions but did not exclude the plaintiffs' ultimate expert opinions concerning trace asbestos and ovarian cancer. That was an admissibility ruling, not a finding that every product contained asbestos, that every exposure caused disease, or that any plaintiff was entitled to recover. Bellwether planning followed, but bankruptcy soon changed the schedule.

2021 to 2023: two LTL bankruptcy cases interrupt the tort docket

In October 2021, a newly created J&J affiliate, LTL Management, filed Chapter 11. The filing followed a corporate restructuring that assigned talc liabilities to LTL, and it produced stays that paused substantial portions of the tort litigation. The U.S. Court of Appeals for the Third Circuit directed dismissal in January 2023 because LTL was not in financial distress of the kind required for good-faith bankruptcy access. A second LTL case filed later in 2023 was also dismissed. Those decisions concerned bankruptcy eligibility and good faith, not the truth of any cancer allegation.

This distinction matters because a stayed MDL can look inactive even while the underlying claims remain unresolved. A bankruptcy can propose a trust, funding, voting procedure, releases, and claim-processing rules. A tort MDL instead manages discovery, motions, expert evidence, and possible trials or remands. Neither path automatically proves exposure or causation. When the first two bankruptcy cases ended, the New Jersey court resumed pretrial work rather than distributing a court-approved global settlement.

2024 to March 2025: renewed science review and the Red River proposal

In March 2024, the MDL court allowed the parties to refile Rule 702 challenges because the evidence rule had been amended and new scientific material had emerged. The parties filed 17 expert motions spanning general causation, product testing and contamination, specific causation, and regulatory or marketing opinions. Separately, IARC announced in July 2024 that its working group classified talc as probably carcinogenic to humans, Group 2A, based on limited human evidence, sufficient animal evidence, and strong mechanistic evidence. IARC identifies hazards; its classification is not an individual legal-causation ruling.

Red River Talc filed a third Chapter 11 case in September 2024 and proposed a bankruptcy resolution for ovarian and other gynecological cancer claims. On March 31, 2025, the bankruptcy court denied confirmation and dismissed the case after finding that the talc claimant class had not validly accepted the plan and identifying broader solicitation and plan problems. The proposed funding figures discussed around that plan never became a generally approved personal-injury payment program. In April 2025, defendants declined to appeal, the stay ended, and the MDL resumed.

2025 to January 2026: a 658-page Rule 702 report

The resumed MDL returned to the question it had paused: which expert opinions should be admitted and within what limits. A retired chief judge serving as special master considered briefs, reports, depositions, a November 25, 2025 hearing, and scientific developments since the 2020 opinion. On January 20, 2026, she filed a 658-page report and recommendation covering dozens of experts and multiple disciplines. A recommendation gives the district judge a developed record and proposed rulings; parties may object, and the presiding judge decides what to adopt.

Readers should resist converting that document into a one-line victory claim. It contains issue-by-issue recommendations about methodology, qualifications, reliability, and fit. Admitting an opinion lets a factfinder consider it; exclusion prevents specified testimony. Neither act determines whether a particular person's use, pathology, exposure route, product identity, alternative risk factors, and governing state law establish liability. State-court proceedings may also apply their own evidentiary rules and schedules.

July 2026 status: the largest active federal MDL, still not one case

JPML's July 1, 2026 report lists 68,435 actions pending and 71,121 historical actions in MDL 2738. The difference does not identify why each action left the pending column; dismissals, transfers, resolutions, and other docket events can all matter. The count also excludes talc cases proceeding solely in state court. A monthly increase or decrease therefore describes federal docket administration, not new scientific proof, an approved settlement inventory, or the number of people who will receive money.

The next reliable milestones are official orders addressing the special master's recommendations, case-management schedules, dispositive motions, bellwether preparation, settlements actually placed on the record, and any remand activity. A state verdict may be important but does not automatically bind every MDL plaintiff. Likewise, the $700 million multistate consumer-protection settlement announced in 2024 resolved government marketing claims and restricted future talc-product sales; it was not a compensation fund for the personal-injury plaintiffs in MDL 2738.

Reader questions

Frequently asked questions